Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 16,697 shares, a decline of 17.9% from the December 15th total of 20,342 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 3,946 shares, the days-to-cover ratio is presently 4.2 days. Based on an average daily volume of 3,946 shares, the days-to-cover ratio is presently 4.2 days. Approximately 0.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MOLN shares. JPMorgan Chase & Co. dropped their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Molecular Partners currently has a consensus rating of “Hold” and an average target price of $7.88.

Molecular Partners Trading Down 3.6%

Molecular Partners stock opened at $4.05 on Wednesday. The firm has a market capitalization of $163.54 million, a P/E ratio of -2.11 and a beta of 1.07. The stock’s fifty day simple moving average is $4.26 and its 200-day simple moving average is $3.93. Molecular Partners has a twelve month low of $3.36 and a twelve month high of $5.41.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.05. Sell-side analysts predict that Molecular Partners will post -1.93 earnings per share for the current year.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.